Clopidogrel: A pharmacogenomic perspective on its use in coronary artery disease

Clinical Medicine Insights: Cardiology

Volumn 4, Issue , 2010, Pages 117-128

  Terpening, Chris ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

ABCB1; Clopidogrel; Cytochrome P4502c19; On treatment platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ALLELE; BRADYCARDIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG USE; DYSPNEA; ETHNIC DIFFERENCE; GASTROINTESTINAL DISEASE; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMICS; RESTENOSIS; REVIEW; SIDE EFFECT;

EID: 78650040544     PISSN: 11795468     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S4323     Document Type: Review

References (68)

1. Fraker TD Jr., Fihn SD. writing on behalf of the Chronic Stable Angina Writing Committee. 2007 Chronic Angina Focused Update of the ACC/ AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina. Circulation. 2007;116(23):2762-2772.
2. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. Stroke. 2008;39(5):1647-1652.
3. The European Stroke Organisation Executive Committee, European Stroke Organization Writing Committee. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovasc Dis. 2008;25(5):457-507.
4. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revasculariza-tion. Eur Heart J. 2010;31(20):2501-2555.
5. Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120(22):2271-2306.
6. Kerr JL, Oppelt TE, Rowen RC. Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. Pharmacotherapy. 2004;24(8):1037-1049.
7. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for Coronary Stenting: Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity. Circulation. 2003;107(23):2908-2913.
8. Oqueli E, Hiscock M, Dick R. Clopidogrel Resistance. Heart Lung Circ. 2007;16 Suppl 3:S17-S28.
9. Kazui M, Nishiya Y, Ishizuka T, et al. Identifcation of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite. Drug Metab Disp. 2010;38(1):92-99.
10. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113(3):340-345.
11. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 Polymorphisms and Response to Clopidogrel. N Engl J Med. 2009;360(4):354-362.
12. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. N Engl J Med. 2009; 360(4):363-375.
13. Momary KM, Dorsch MP, Bates ER. Genetic causes of clopidogrel nonresponsiveness: which ones really count? Pharmacotherapy. 2010;30(3): 265-74.
14. CYP2C19 allele nomenclature. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee [2010 Aug 24; http://www.cypalleles.ki.se/cyp2c19.htm]. Accessed 2010 Oct 13.
15. Xie H-G, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharm Toxicol. 2001; 41(1):815-850.
16. Mizutani T. PM Frequencies of Major CYPs in Asians and Caucasians. Drug Metabol Rev. 2003;35(2-3):99-106.
17. Verstuyft C, Simon T, Kim RB. Personalized medicine and antiplatelet therapy: ready for prime time? Eur Heart J. 2009;30(16):1943-1963.
18. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010;69(3):222-230.
19. Hulot J-S, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of- function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244-2247.
20. Kim KA, Park PW, Hong SJ, Park JY. The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance. Clin Pharmacol Ther. 2008;84(2):236-42.
21. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of Cytochrome P450 2C19 Genotype with the Antiplatelet Effect and Clinical Effcacy of Clopidogrel Therapy. JAMA. 2009;302(8):849-57.
22. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation. 2010;121(4):512-8.
23. Sof F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 2010. E-published 2010 Mar 30. doi:10.1038/tpj.2010.21.
24. Hulot J-S, Collet J-P, Silvain J, et al. Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration: A Systematic Meta-Analysis. J Am Coll Cardiol. 2010;56(2):134-43.
25. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749):1320-8.
26. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. New England Journal of Medicine. 2010. E-published 2010 Aug 29. doi:10.1056/NEJMoa1008410.
27. The Clopidogrel in Unstable angina to prevent Recurrent Events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
28. ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med. 2009;360(20):2066-2078.
29. Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010;160(3):506-512.
30. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. (BBA)-Proteins and Proteomics. 2009;1794(5):860-871.
31. Tang K, Wong LP, Lee EJD, Chong SS, Lee CGL. Genomic evidence for recent positive selection at the human MDR1 gene locus. Human Mol Genetics. 2004;13(8):783-797.
32. Komoto C, Nakamura T, Sakaeda T, et al. MDR1 Haplotype Frequencies in Japanese and Caucasian, and in Japanese Patients with Colorectal Cancer and Esophageal Cancer. Drug Metab Pharmacokinet. 2006;21(2): 126-132.
33. Woodahl EL, Ho RJY. The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function. Curr Drug Metab. 2004;5(1):11-19.
34. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80(5):486-501.
35. Spiewak M, Malek L, Kostrzewa G, et al. Infuence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Kardiol Pol. 2009; 67(8):827-834.
36. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312-1319.
37. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp C. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost. 2010;8(1):37-42.
38. Suh J-W, Koo B-K, Zhang S-Y, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006;174(12):1715-1722.
39. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894-1909.
40. Gilard M, Arnaud B, Cornily J-C, et al. Infuence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study. J Am Coll Cardiol. 2008;51(3):256-260.
41. Liu TJ, Jackevicius CA. Drug interaction between clopidogrel and proton pump inhibitors. Phamacotherapy. 2010;30(3):275-289.
42. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med. 2010.
43. Hochholzer W, Trenk D, Fromm MF, et al. Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. J Am Coll Cardiol. 2010;55(22): 2427-34.
44. Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diabet Vasc Dis Res. 2010. E-published 2010 Oct 4. doi:10.1177/1479164110383994.
45. Serebruany V, Cherala G, Williams C, et al. Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of "resistance". Am Heart J. 2009;158(6):925-932.
46. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents: A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians. Circulation. 2007;115(6):813-818.
47. Kolandaivelu K, Bhatt DL. Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol. 2010;7(8): 461-467.
48. Aradi D, Komócsi A, Vorobcsuk A, et al. Prognostic signifcance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J. 2010;160(3): 543-551.
49. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA. 2010;303(8):754-762.
50. Sibbing D, Steinhubl SR, Schulz S, Schömig A, Kastrati A. Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients: Initial Evidence of a Therapeutic Window. J Am Coll Cardiol. 2010;56(4):317-318.
51. Bonello L, Tantry US, Marcucci R, et al. Consensus and Future Directions on the Defnition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. J Am Coll Cardiol. 2010;56(12):919-933.
52. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: One Piece of the Puzzle to Personalize Antiplatelet Therapy. J Am Coll Cardiol. 2010; 56(2):112-116.
53. CURRENT-OASIS 7 Investigators. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. N Engl J Med. 2010;363(10): 930-942.
54. Mehta SR, Tanguay J-F, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233-1243.
55. Lotrionte M, Biondi-Zoccai GGL, Agostoni P, et al. Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2007;100(8):1199-206.
56. Gladding P, Webster M, Zeng I, et al. The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response: An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial. JACC: Cardiovasc Inter-vent. 2008;1(6):620-627.
57. Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19*2 Loss of Function Polymorphism. J Am Coll Cardiol. 2010. E-published 2010 Aug 11. doi:10.1016/j.jacc.2010.07.004.
58. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321-341.
59. Geeganage C, Wilcox R, Bath P. Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Med. 2010; 8(1):36.
60. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of Polyunsaturated Omega-3 Fatty Acids on Responsiveness to Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: The OMEGA-PCI (OMEGA-3 Fatty Acids After PCI to Modify Responsiveness to Dual Antiplatelet Therapy) Study. J Am Coll Cardiol. 2010;55(16):1671-1678.
61. Jennings DL, Kalus JS. Addition of Cilostazol to Aspirin and a Thienopyri-dine for Prevention of Restenosis After Coronary Artery Stenting: A Meta-Analysis. J Clin Pharmacol. 2010;50(4):415-521.
62. Lee S-W, Park S-W, Yun S-C, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J. 2010;159(2):284-291.e281.
63. Yoo H-D, Cho H-Y, Lee Y-B. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol. 2010;69(1):27-37.
64. Hwang S-J, Jeong Y-H, Kim I-S, et al. Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2010;3(5):450-459.
65. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15; 357(20):2001-2015.
66. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes. Circulation. 2009;119(19): 2553-2560.
67. Sorich M, Vitry A, Ward M, Horowitz J, McKinnon R. Prasugrel versus clopidogrel for cytochrome P450 2C19 genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost. 2010;8(8):1678-84.
68. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361(11): 1045-57.